← Back to patent-cliff list
Thymosin alpha 1
Tier C — Watch / tradeThymosin alpha 1
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Non-small cell lung cancer, Hepatitis B
Regional status
US
-
EU
-
China
Phase II
2023-07-25
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Also available in our peptide catalogue
Frequently asked questions
What are the approved indications of Thymosin alpha 1?
Approved indications include: Non-small cell lung cancer, Hepatitis B.
When does the Thymosin alpha 1 patent expire?
No public expiry year is available for Thymosin alpha 1 yet; this page updates once verified.
How do I get a quote for Thymosin alpha 1 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02